timothy sykes logo

Stock News

SLNO’s Unexpected Surge: Should You Reconsider?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 3/27/2025, 9:18 am ET 3/27/2025, 9:18 am ET | 5 min 5 min read
SLNO’s Unexpected Surge: Should You Reconsider? Thumbnail

Soleno Therapeutics Inc.’s stock price is notably influenced by news that the company is making significant strides in its clinical trials, likely driving the positive market sentiment. On Thursday, Soleno Therapeutics Inc.’s stocks have been trading up by 35.96 percent.

Positive Market Developments

  • The long-awaited FDA approval of VYKAT XR for treating hyperphagia in Prader-Willi syndrome has given a significant boost to Soleno Therapeutics’ standing. This approval marks a notable achievement for SLNO, setting the stage for the drug’s U.S. launch in April 2025.

Candlestick Chart

Live Update At 09:18:21 EST: On Thursday, March 27, 2025 Soleno Therapeutics Inc. stock [NASDAQ: SLNO] is trending up by 35.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Following the FDA’s nod to VYKAT XR, SLNO experienced a temporary halt in share trading. Upon resumption, shares skyrocketed by 35%, indicating strong market optimism for the newly approved therapy.

  • Stifel, in reclaiming their analytical gaze on Soleno Therapeutics, has renewed their optimistic ‘Buy’ rating. A robust $74 price target underscores their confidence, buoyed by an 80% anticipated approval likelihood for DCCR, targeted toward Prader-Willi Syndrome treatment.

  • Earnings have dipped deeper into the negatives in Soleno Therapeutics’ Q4 financial statements, a consequence softened by the impending FDA decision regarding their product line, particularly the awaited nod for DCCR therapy.

Earnings and Financial Metrics Overview

As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” This principle is fundamental for traders who aim to succeed in the market, emphasizing that careful planning and the ability to wait for the right opportunities play crucial roles in achieving significant returns. By focusing on thorough analysis and timing, traders can enhance their potential for success.

Soleno Therapeutics Inc.’s recent financial data paints a tale of both hope and caution. Revenue-related values weren’t directly expressive, but notable financial deductions are evident in their financial statements. While the company faced losses, they’ve maintained vigorous efforts in research and development.

Financial Parameters

Financially strong, Soleno sustains a current ratio of 15.7 and a quick ratio of 15.6, proving their capability to meet short-term obligations. However, the firm faces notably negative figures in return on assets (-46.05%) and return on equity (-61.75%), among other key metrics, which warrant caution for potential investors.

Intraday Stock Analysis

During the trading day, spikes in share prices confirmed market vigor and speculative enthusiasm around SLNO stock. SLNO’s trading pattern demonstrated marked volatility, an indication of how FDA news resonates with investor sentiment, pulling the stock price to new highs reminiscent of the pharmaceutical realm’s unpredictable but rewarding nature.

More Breaking News

Asset and Liabilities

Breaking down SLNO’s balance sheet, total assets stood at $330.97M against liabilities of $85.86M, reasserting their asset advantage. Frequent asset turnover coupled with prudent long-term debt management indicates a stable albeit challenging footing in navigating future financial ventures.

Key Market Sentiments

FDA Approval’s Ripple Effect

Soleno’s recent FDA approval for VYKAT XR has sent waves through the market. Stock value surged post-approval, marked by swift reactions as traders rallied behind the novelty and promise such engagements bring to healthcare innovations.

Visionary Market Moves

Analysts like Stifel have captured this venture’s essence, reflecting bullish outlooks tireless in their zest toward solving long-standing therapeutic challenges. Such investments in forward-leaning research enhance Soleno’s credibility, potentially catalyzing new partnerships or funding opportunities within the healthcare industry.

Financial Turnarounds in Play

Soleno’s fiscal synthesis clearly situates potential among prevailing deficiencies. Though negative earnings persist, bright spots in clinical success could transition future outlooks. This intricate dance between risk and reward encapsulates pharmaceutical industry norms, leading many to watch SLNO’s trajectory closely.

In conclusion, SLNO’s market positioning rests heavily on regulatory triumphs and the subsequent burning potential for future growth. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” Analysts and traders must consider the combined weight of tangible financial metrics, along with intraday movements, to evaluate whether this surge aligns strategically within broader portfolio objectives. While enthusiasm abounds, deliberate calculations are pivotal when gauging prospects with dynamically intertwined financial fields — particularly in pharmaceutical contexts where data and regulatory acclaim shape vast financial landscapes.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”